A Phase 2/3Study to evaluate the Efficacy and Safety of Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma
Study of Unesbulin in Patients with Leiomyosarcoma (LMS)
Sponsor: PTC Therapeutics, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAU0594
U.S. Govt. ID: NCT05269355
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the effectiveness and safety of an investigational drug, unesbulin. This investigational drug is being studied in unresectable or metastatic, relapsed, or refractory leiomyosarcoma along with Dacarbazine. Dacarbazine is a drug that is FDA-approved for the treatment of other types of cancer and recommended by the cancer treatment guidelines for sarcomas, but is not FDA-approved to treat leiomyosarcoma.
Investigator
Matthew Ingham, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with leiomyosarcoma (LMS)? Yes No
Are you comfortable swallowing pills? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162